Mylan said Nov. 12 that when it merges with Pfizer's Upjohn unit, the combined company will be called Viatris.
The companies said the name is derived from the Latinwords via, meaning path, and tris, meaning three, to signify the company's three core goals: expanding access to medicines, leading by innovating to meet patient needs and being a trusted partner for the healthcare community.
The companies have not yet announced where Viatris will be headquartered, besides that it will be in the U.S., according to the Pittsburgh Post-Gazette.
Mylan and Pfizer said more information on Viatris, including the company's full executive management team, board of directors, stock symbol and logo will be announced at a later date.
The merger is expected to be finalized in mid-2020.
Read the full news release here.